Agilent’s PD-L1 IHC 28-8 pharmDx Companion Diagnostic Assay Earns European IVDR Certification
Agilent Technologies today announced the issuance of a Class C Companion Diagnostic (CDx) In Vitro Diagnostic Regulation (IVDR) certification for its PD-L1 IHC 28-8 pharmDx (Code SK005) assay. This diagnostic…
Friends of Traditional Medicine Set 2025 Action Agenda
On November 29, the Group of Friends of Traditional Medicine convened in Geneva to explore opportunities for joint action in 2025, fostering collaboration and coordination among WHO Member States. Ambassadors…
Bio-Techne Unveils ESR1 Mutation Monitoring Assay
Bio-Techne Corporation announced the launch of a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. This innovative assay is designed for research use and aims to detect ESR1…
SILAL and Bayer Strengthen Agricultural Partnership with MOU
Silal and Bayer have reinforced their commitment to agricultural innovation in the UAE with the signing of a comprehensive Memorandum of Understanding (MoU) at the World Agri-Tech Innovation Summit in…
Roche Highlights Columvi & Lunsumio Data at ASH 2024 for Lymphoma Treatment
Roche presented new and updated findings from its pioneering CD20xCD3 T-cell-engaging bispecific antibody program at the 66th American Society of Hematology (ASH) Annual Meeting, held from December 7-10, 2024. With…
Biogen Names Tim Power as Head of Investor Relations
Biogen has appointed Tim Power as Vice President and Head of Investor Relations, effective December 9, 2024. In this role, Mr. Power will report directly to Michael McDonnell, the company’s…
CARVYKTI Boosts MRD Negativity in Relapsed Multiple Myeloma
Legend Biotech Corporation a global leader in cell therapy, recently unveiled groundbreaking results from the Phase 3 CARTITUDE-4 clinical trial, further cementing the efficacy of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in…
Epcoritamab Shows Durable Responses in Large B-Cell Lymphoma Trials
At the 66th Annual Meeting of the American Society of Hematology (ASH), AbbVie shared new data from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody. Administered subcutaneously,…
Pozelimab-Cemdisiran Combo Surpasses Ravulizumab in Controlling PNH Hemolysis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced updated Phase 3 data from the ACCESS-1 trial, showing that its investigational combination of pozelimab and cemdisiran (poze-cemdi) outperforms the standard-of-care C5 inhibitor, ravulizumab,…
Kite Presents New Data on Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH
Kite, a Gilead Company presented new findings from three analyses on Yescarta® (axicabtagene ciloleucel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) at the 66th Annual Meeting & Exposition…
Epcoritamab Combination Therapy Shows High Response Rates in R/R Follicular Lymphoma Trial
Genmab has announced promising results from the Phase 1b/2 EPCORE® NHL-2 trial, which evaluated a fixed-duration regimen of epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab…
Epcoritamab Monotherapy Shows High Response Rates in R/R CLL Trial
Genmab has announced promising results from the Phase 1b/2 EPCORE® CLL-1 clinical trial evaluating epcoritamab, a T-cell engaging bispecific antibody, in patients with relapsed or refractory chronic lymphocytic leukemia (R/R…